| __timestamp | ADMA Biologics, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 3742367 | 179279000 |
| Thursday, January 1, 2015 | 4311461 | 186359000 |
| Friday, January 1, 2016 | 6360761 | 171785000 |
| Sunday, January 1, 2017 | 29164321 | 208136000 |
| Monday, January 1, 2018 | 42194635 | 198405000 |
| Tuesday, January 1, 2019 | 39504238 | 224169000 |
| Wednesday, January 1, 2020 | 61291426 | 245044000 |
| Friday, January 1, 2021 | 79769341 | 252314000 |
| Saturday, January 1, 2022 | 118814535 | 268225000 |
| Sunday, January 1, 2023 | 169273000 | 304629000 |
| Monday, January 1, 2024 | 324203000 |
Unlocking the unknown
In the competitive landscape of pharmaceuticals, cost efficiency is paramount. ADMA Biologics, Inc. and Taro Pharmaceutical Industries Ltd. have shown contrasting trajectories in their cost of revenue from 2014 to 2023. ADMA Biologics, Inc. started with a modest cost of revenue, but by 2023, it surged by over 4,400%, reflecting their aggressive expansion and scaling strategies. In contrast, Taro Pharmaceutical Industries Ltd. maintained a more stable growth, with a 70% increase over the same period, showcasing their consistent operational efficiency.
While ADMA's rapid growth is impressive, it also highlights the challenges of managing costs in a fast-expanding company. Taro's steadier increase suggests a more controlled approach, possibly indicating a focus on sustainable growth. As we look to 2024, Taro's data remains robust, while ADMA's is notably absent, leaving room for speculation on their future strategies.
Cost of Revenue Comparison: AstraZeneca PLC vs Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down Pfizer Inc. and Taro Pharmaceutical Industries Ltd.'s Expenses
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and ADMA Biologics, Inc.
Cost Insights: Breaking Down Bio-Techne Corporation and ADMA Biologics, Inc.'s Expenses
Catalent, Inc. vs ADMA Biologics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: ADMA Biologics, Inc. vs Geron Corporation
Cost of Revenue Comparison: ADMA Biologics, Inc. vs Mesoblast Limited
Xenon Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: MorphoSys AG vs Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for Vericel Corporation and Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down Taro Pharmaceutical Industries Ltd. and Dyne Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Celldex Therapeutics, Inc.